Kalaris Therapeutics, Inc.  - Common Stock
Kalaris Therapeutics, Inc. - Common Stock
Share · US4829291065 · KLRS (XNAS)
Overview
No Price
19.12.2025 22:03
Current Prices from Kalaris Therapeutics, Inc. - Common Stock
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
KLRS
USD
19.12.2025 22:03
9,12 USD
-1,30 USD
-12,48 %
Share Float & Liquidity
Free Float 24,74 %
Shares Float 4,63 M
Shares Outstanding 18,7 M
Company Profile for Kalaris Therapeutics, Inc. - Common Stock Share
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
AI Analysis of Kalaris Therapeutics, Inc. - Common Stock
Click any analysis below to get instant AI insights from finAgent

Company Data

Name Kalaris Therapeutics, Inc. - Common Stock
Company Kalaris Therapeutics Inc
Symbol KLRS
Website https://www.allovir.com
Primary Exchange XNAS NASDAQ
ISIN US4829291065
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Andrew Oxtoby
Market Capitalization 49 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 139 Main Street, Suite 500, 02142 Cambridge
IPO Date 2020-07-30

ID Changes

Date From To
19.03.2025 ALVR KLRS

Ticker Symbols

Name Symbol
NASDAQ KLRS
More Shares
Investors who hold Kalaris Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:
CONVERGE TECHNOLOGIESLOGY SOL.
CONVERGE TECHNOLOGIESLOGY SOL. Share
ENERGY TRANSFER PAR. 2045
ENERGY TRANSFER PAR. 2045 Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025